Etazolate hydrochloride is an orally active and selective phosphodiesterase type 4 (PDE4) inhibitor (IC50 = 2 μM); a γ-aminobutyric acid A (GABAA) receptor modulator; an α-secretase activator that induces the production of soluble amyloid precursor protein alpha (sAPPα); and a pyrazolopyridine derivative that increases intracellular cAMP levels. It exhibits anxiolytic-like, antidepressant-like, and anti-inflammatory effects.